Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683392 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL11099691 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL5155598 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL12235723 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL15909556 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL12824048 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL584549 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL6421616 | 0.90 | NR1H2 (0.48) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1722772 | 0.87 | CYP1A2 (0.45) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL20371652 | 0.87 | CYP1A2 (0.45) | NR1H2CYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525852-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023224893-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| WO-2021152165-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2021-08-05 | — | — | WO | disclosed |
| US-20200331910-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | UNIV NORTHWESTERN (US) | 2020-10-22 | — | — | US | disclosed |
| US-10759791-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3486244-A1 | NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-05-22 | — | — | EP | disclosed |
| EP-2708540-B1 | PYRIMIDO-DIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-9951014-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2811997-B1 | SUBSTITUTED PROLINES/PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | EOLAS THERAPEUTICS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1615878-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | ANADYS PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
| WO-2005028467-A1 | ANTIBACTERIAL 3,5-DIAMINOPIPERIDINE-SUBSTITUTE AROMATIC AND HETEROAROMATIC COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004064730-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| CN-1171112-A | Amino acid nucleic acids | ICN PHARMACEUTICALS CO (US) | 1998-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331910-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NOS1, NOS2, NOS3 | NR1H2 459/4885CYP1A2 346/4885POLB 659/4885 |
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | NR1H2 2916/4885CYP1A2 4607/4885POLB 3797/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | NR1H2 1410/4885CYP1A2 1202/4885POLB 3729/4885 |
| US-10759791-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | NR1H2 459/4885CYP1A2 346/4885POLB 659/4885 |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | AMPD3, AAAS, PEPD | NR1H2 4112/4885CYP1A2 758/4885POLB 284/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | NR1H2 2912/4885CYP1A2 4662/4885POLB 3536/4885 |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | NR1H2 2632/4885CYP1A2 4529/4885POLB 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.